Primary octreotide LAR therapy in GH-secreting pituitary adenoma.

Abstract

A case of a 54-year-old male with active acromegaly and severe aortic stenosis treated primarily with octreotide LAR 20 mg/ IM/month for six months is reported here. His serum growth hormone level declined and was sustained throughout the period of six months (basal GH level 21.8 ng/ml; 1.2 ng/ml six months after therapy; mean+/-SD during six months of therapy 1.36+/-0.34 ng/ml; range 0.9 - 1.9 ng/ml). The post-treatment, postgadolinium, T1 weighted sagittal magnetic resonance images showed disappearance of the growth hormone secreting adenoma. The use of octreotide LAR as primary therapy in active acromegaly is discussed along with a brief review of literature.

• Authors: C V Harinarayan
• Journal: Journal of the Indian Medical Association (J Indian Med Assoc) Vol. 102 Issue 5 Pg. 258, 260-1 (May 2004) ISSN: 0019-5847 [Print] India
• PMID: 15636029 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents, Hormonal
• Human Growth Hormone
• Octreotide

Topics

• Acromegaly (drug therapy, etiology)
• Adenoma (complications, drug therapy, metabolism)
• Antineoplastic Agents, Hormonal (pharmacology)
• Human Growth Hormone (blood, metabolism)
• Humans
• Male
• Middle Aged
• Octreotide (pharmacology)
• Pituitary Neoplasms (complications, drug therapy, metabolism)